ABCL AbCellera Biologics Inc. stock chart & analysis
Conviction 48HealthcareScan · Fri, Nov 6, 2026AbCellera Biologics Inc. (ABCL) closed at $11.88 (+6.74%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 48, RS Rating 99, -20.9% from its 52-week high, +247.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why ABCL moved
From the StockSetups movers recaps that covered ABCL, newest first. A recap states what was known that day.
- Close+34.7%
Multiple sources converged on the same catalyst. Bloomberg reported the stock rose as much as 41% after a hot-flash drug trial result; Yahoo Finance described AbCellera "rocketing" on news that a hot-flash (menopause) treatment hit all primary and secondary goals in its clinical trial.
Top Stock Movers Today — August 10, 2026: Why JWEL, BWMN, VREX, HZO & ABCL Surged →
Financials as of Tue, Jun 30, 2026 · quarterly.
ABCL technical analysis
Trend
ABCL's moving averages are mixed — no clean uptrend or downtrend. It closed 3.2% below the 50-day ($12.28) and 68.8% above the 200-day ($7.04). ADX(14) at 14 points to a weak trend — more range than direction. It meets 7 of 8 trend-template criteria.
Momentum
RSI(14) is 48, in the bearish half of its range. MACD crossed below its signal line 4 sessions ago. A bullish MACD divergence is in place. Its RS Rating of 99 puts its weighted 12-month performance ahead of about 99% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $42.9M a day on average. ATR(14) is $0.9518, 8.0% of price — its typical daily range. Bollinger Bands are in a squeeze (5 sessions) — volatility is compressed. Chaikin Money Flow (0.05) shows accumulation.
Key levels
The chart pattern's support is $11.07 and its resistance $14.77. The 52-week range is $2.75 to $15.02; price is 20.9% below the high and 332.8% above the low. The VWAP anchored at the 52-week high is $12.66, above price.
Performance
ABCL returned -3.2% (1 week), -1.2% (1 month), +27.2% (3 months), +126.7% (6 months), +153.3% (1 year), +247.4% (year to date).
About AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Pharmaceutical Preparations · Listed 2020 · 562 employees
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Breaking out nowAug 25 – Sep 172 scans
- Setting upSep 23 – Sep 253 scans
- Breaking out nowSep 281 scan
Insider activity
SEC Form 4 transactions in ABCL · open-market 4 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Hayden Michael R Director · Common Shares · 2026-08-24 | Buy | 53.61K | $570K | 2026-08-24 | 2026-08-24 |
Montalbano John S. Director · Common Shares · 2026-08-18 | Buy | 10K | $110K | 2026-08-18 | 2026-08-18 |
Booth Andrew Chief Financial Officer · Common Shares · 2026-08-14 | Buy | 37.2K | $384K | 2026-08-14 | 2026-08-14 |
Hayden Michael R Director · Common Shares · 2026-08-12 | Buy | 46.39K | $481K | 2026-08-12 | 2026-08-14 |
Hayden Michael R Director · Common Shares · 2026-08-11 | Gift | 50K | — | 2026-08-11 | 2026-08-13 |
Sandor Victor Director · Share option (right to buy) · 2026-07-01 | Grant | 152.21K | — | 2026-07-01 | 2026-07-06 |
Seely Lynn Director · Share option (right to buy) · 2026-07-01 | Grant | 152.21K | — | 2026-07-01 | 2026-07-06 |
Hayden Michael R Director · Share option (right to buy) · 2026-06-11 | Grant | 111.7K | — | 2026-06-11 | 2026-06-12 |
Quake Stephen Director · Share option (right to buy) · 2026-06-11 | Grant | 111.7K | — | 2026-06-11 | 2026-06-12 |
Montalbano John S. Director · Share option (right to buy) · 2026-06-11 | Grant | 111.7K | — | 2026-06-11 | 2026-06-12 |
SEC filings
EDGAR filings in ABCL · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.